Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation THKKF


Primary Symbol: V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Post by dt_coreon Feb 15, 2022 12:27pm
181 Views
Post# 34430407

Price Decline

Price DeclineLight volume continues and the share price has fallen from $1.21 to $1.07 in short order with an average daily volume of only 20,000 shares traded vs. the stocks usual 75,000 to 80,000 shares traded daily range. Management has their work cut out for them if they are going to turn this sinking share price around. I'm sure RN would agree that a sinking share price implies a sinking ship!

So far the market is being proved correct since the company hasn't been doing much of anything to support its stock. I recognize that its quiet period, given earnings are due, but even a statement saying that trading has been unusual AND/OR that the share price is not reflecting fundamentals AND/OR perhaps even an earnings pre-release with ideally an uptick in guidance for 2022 if things are as robust as SA suggested in December at the investor conference. Investors like myself want to see some evidence before increasing our stakes and blamming the share price decline on a now past tax loss selling season or on previous insider selling has clearly proven to be hogwash. And management can't go blamming the market either, that is a cop-out. given the firms trading multiples are no where near the peers management has  mentioned. 

So to SA and management of THNK, the market has spoken and they are decidedly not in favour of what they see the company or its leaders doing. Will the market be proved right? How will you respond? Will you even respond? 
<< Previous
Bullboard Posts
Next >>